Skip to main content
EJNMMI Research
Fig. 2 | EJNMMI Research

Fig. 2

From: Impact of non-regional lymph node metastases accurately revealed on 18F-PSMA-1007 PET/CT in the clinical management of metastatic hormone-sensitive prostate cancer

Fig. 2

Kaplan‒Meier estimates of the impact of non-regional lymph node (NRLN) metastases on progression-free survival (PFS) for all patients with mHSPC in this study (A), patients with low-volume disease (B), and patients with high-volume disease (C). PFS was compared between patients with low-volume disease plus NRLN metastases and patients with high-volume disease (D). PFS was compared among patients with low-volume disease and NRLN metastases by different treatment arms (E)

Back to article page